Allergan Aesthetics, a subsidiary of AbbVie (NYSE:ABBV), has reported results from two Phase 4 clinical studies evaluating aesthetic treatments in adults taking glucagon-like peptide-1 (GLP-1) medications, with both studies showing improvements in patient-reported satisfaction with facial appearance.
The findings, presented at the 2026 American Society for Dermatologic Surgery Annual Meeting in San Diego, included data from the HARMONY IN DIVERSITY study and an interim analysis of the HALO study.
The research examined injectable aesthetic treatments and skincare approaches for individuals taking GLP-1 medications, which are commonly prescribed for weight management and other conditions.
The Phase 4 HARMONY IN DIVERSITY study evaluated a combined aesthetic treatment regimen in 30 adults receiving stable doses of GLP-1 medications.
The treatment approach included hyaluronic acid (HA) injectable products, onabotulinumtoxinA and a skincare routine specified by the study protocol.
Researchers assessed changes in patient-reported outcomes using the FACE-Q Satisfaction With Facial Appearance scale, which measures participants’ perceptions of their facial appearance.
At 30 days following treatment, participants recorded a mean improvement of 42.4 points from baseline on the FACE-Q scale.
According to Allergan Aesthetics, the improvement was statistically significant.
The study also identified statistically significant improvements in measures of skin quality, psychological function and social function.
Most treatment-related adverse events were classified as mild and resolved without medical intervention.
The findings provide information about patient-reported outcomes following a combined aesthetic treatment approach in adults taking GLP-1 medications.
Allergan Aesthetics also presented interim results from the Phase 4 HALO study, which is evaluating hyaluronic acid injectable treatments in adults using GLP-1 medications.
The planned study population consists of 75 participants, with the interim analysis covering 25 adults.
At three months following treatment, participants recorded a mean improvement of 39.6 points from baseline in FACE-Q Satisfaction With Facial Appearance scores.
The analysis also assessed participants’ perceptions of whether the treatments preserved their individual appearance.
According to the company, 95.7% of participants reported being satisfied or very satisfied that they continued to look like themselves following treatment.
Additionally, 82.6% said they were satisfied or very satisfied with how natural their appearance looked.
Most adverse events reported at the time of the interim analysis were mild and nonserious.
The results represent an interim assessment of the study, with additional data expected as the planned participant population completes treatment and follow-up.
The studies address aesthetic considerations among people taking GLP-1 medications, including those prescribed for weight loss.
According to a publication referenced by Allergan Aesthetics in Aesthetic Surgery Journal Open Forum, individuals using GLP-1 treatments for weight management may experience changes in facial appearance, including reduced facial volume and alterations in skin quality.
Such changes can occur alongside weight reduction and may influence patients’ perceptions of their facial appearance.
The HARMONY IN DIVERSITY and HALO studies evaluated whether aesthetic treatment approaches were associated with improvements in patient-reported satisfaction among adults receiving GLP-1 therapy.
The studies measured aesthetic outcomes rather than the effectiveness of GLP-1 medications for weight management.
The reported results also do not establish how the treatments compare with no aesthetic intervention over longer periods, beyond the comparisons and follow-up information provided in the announcement.
Allergan Aesthetics presented further research at the dermatologic surgery meeting covering several areas of aesthetic medicine.
The additional presentations included investigations into multimodal treatment approaches across different skin types.
Researchers also presented data concerning investigational trenibotulinumtoxinE compared with onabotulinumtoxinA for the treatment of glabellar lines, the vertical lines that can appear between the eyebrows.
Other research addressed a topical skincare serum based on exosome technology and the sequencing of treatments used in body contouring procedures.
The announcement did not provide detailed efficacy or safety results for these additional presentations.
Together, the studies covered injectable products, skincare formulations and combinations of aesthetic procedures.
The HARMONY IN DIVERSITY study reported a statistically significant mean improvement of 42.4 points in facial appearance satisfaction 30 days after treatment among 30 participants.
The HALO interim analysis recorded a 39.6-point mean improvement at three months among 25 participants, alongside patient-reported satisfaction with maintaining a natural appearance.
Both studies reported predominantly mild adverse events in the available assessments.
However, the relatively small study populations and the interim status of the HALO analysis are relevant when interpreting the findings.
The supplied announcement did not report a placebo-controlled comparison for either study, limiting conclusions about the extent to which the observed improvements can be attributed specifically to the treatments.
Further follow-up and complete study results may provide additional information about the duration of treatment effects and the safety findings.
The Phase 4 results add to Allergan Aesthetics’ clinical research involving adults taking GLP-1 medications.
The HARMONY IN DIVERSITY study evaluated a combined regimen of injectable treatments and skincare, while HALO focused on hyaluronic acid injectables.
Both reported improvements in patient satisfaction with facial appearance, with the available safety findings indicating that most reported adverse events were mild.
The company also presented research involving other injectable products, skincare technologies and treatment combinations at the 2026 dermatologic surgery meeting.
The completed HALO study and any subsequent follow-up analyses will provide further data on aesthetic treatment outcomes in this patient population.
AbbVie stock price
| 7 hours | |
| Nov-08 | |
| Nov-06 | |
| Nov-05 | |
| Nov-04 | |
| Nov-03 | |
| Nov-03 | |
| Nov-03 | |
| Oct-30 | |
| Oct-30 | |
| Oct-30 | |
| Oct-30 | |
| Oct-30 |
AbbVie's Earnings Double As Immunology Powerhouse Skyrizi Beats Again
ABBV
Investor's Business Daily
|
| Oct-30 | |
| Oct-30 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite